Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has received a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $10.00.

A number of research firms recently weighed in on AMRX. Piper Sandler upped their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. StockNews.com lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 19th.

Amneal Pharmaceuticals Stock Down 3.7 %

Amneal Pharmaceuticals stock opened at $8.26 on Monday. The stock has a 50 day moving average of $8.16 and a two-hundred day moving average of $8.22. Amneal Pharmaceuticals has a twelve month low of $5.01 and a twelve month high of $9.48.

Insider Transactions at Amneal Pharmaceuticals

In related news, SVP Jason B. Daly sold 43,657 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $8.61, for a total value of $375,886.77. Following the completion of the sale, the senior vice president now owns 13,665 shares of the company’s stock, valued at approximately $117,655.65. The trade was a 76.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Gautam Patel sold 17,410 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $8.01, for a total transaction of $139,454.10. Following the transaction, the director now owns 2,031,476 shares in the company, valued at approximately $16,272,122.76. This trade represents a 0.85 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 123,657 shares of company stock valued at $1,016,687. Company insiders own 17.46% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of AMRX. Franklin Resources Inc. grew its holdings in Amneal Pharmaceuticals by 4.9% during the 3rd quarter. Franklin Resources Inc. now owns 89,887 shares of the company’s stock worth $778,000 after acquiring an additional 4,178 shares during the last quarter. Gladius Capital Management LP bought a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter valued at $37,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in shares of Amneal Pharmaceuticals by 13.6% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 46,240 shares of the company’s stock valued at $366,000 after purchasing an additional 5,523 shares in the last quarter. Segall Bryant & Hamill LLC increased its position in shares of Amneal Pharmaceuticals by 1.6% during the third quarter. Segall Bryant & Hamill LLC now owns 489,162 shares of the company’s stock worth $4,070,000 after acquiring an additional 7,661 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of Amneal Pharmaceuticals by 3.5% in the fourth quarter. Rhumbline Advisers now owns 232,264 shares of the company’s stock valued at $1,840,000 after purchasing an additional 7,875 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.